Amicus Therapeutics announces leadership updates

Cranbury-based Amicus Therapeutics, a biotechnology company, announced it has named Daphne Quimi to chief financial officer, effective Jan. 1, 2019.

Quimi will succeed Chip Baird, who is leaving the company to pursue other opportunities. She will report to John F. Crowley, chairman and CEO.

“Amicus has never been in a stronger financial position, thanks to the leadership of Chip, Daphne and our extraordinary global finance team. We have become a truly worldwide company now with operations in more than 27 countries and world class financial reporting, controls and accounting systems. Our balance sheet has never been more sound,” Crowley said. “Daphne has been instrumental in building this global finance organization during her tenure at Amicus. Her extensive executive experience will help lead us through the next chapter of our growth and toward our vision to become one of the world’s leading biotechnology companies focused on rare diseases. I am confident that the hand-off from Chip to Daphne will be smooth. I will remain forever grateful to Chip for his extraordinary leadership and passion for patients and wish him well in his future endeavors.  He leaves Amicus in a very strong position.”

“I am proud to have been a part of the Finance team as we have transitioned to a public company and now into a global commercial company. I look forward to taking on the responsibilities of Chief Financial Officer as we continue to execute the Galafold launch, move our Pompe program into Phase 3, and advance our gene therapy pipeline,” Quimi said.

Quimi has been with Amicus for 11 years, most recently serving as senior vice president, finance and administration. Prior to that, she was director of finance at Bristol-Myers Squibb. She also held roles in finance at Johnson & Johnson.

“We have accomplished a great deal at Amicus over the last seven years. Working with John and the rest of the leadership team, we have transformed Amicus from a US-based R&D company to a global commercial company with one of the strongest pipelines in rare disease. With a very strong balance sheet, a growing commercial business in Galafold, and a capable finance leader like Daphne, Amicus is well-positioned to deliver on the next phase of its patient-focused mission,” Baird said.

The company also announced additional organizational updates and promotions, including:

  • David Clark appointed to chief people officer;
  • Ellen Rosenberg promoted to chief legal officer;
  • Andrew E. Mulberg promoted to senior vice president, global regulatory affairs;
  • Anthony Sileno promoted to senior vice president, clinical operations and translational sciences.

Clark will report to Crowley, the company said. Before joining Amicus, Clark was vice president of global human resources at Alibaba Group. Previously, he spent time with American Express, including roles such as senior vice president of HR and chief learning officer. Before that, he was a commissioned officer on the White House senior staff.

“I am pleased to welcome David to Amicus as our first-ever chief people officer. He will be a tremendous asset to our organization as we continue to grow our global team while affirming our patient-dedicated culture. I would also like to congratulate Ellen, Andrew and Anthony on their promotions. All of them are exceptional leaders and provide expertise that add significant value within their respective functions and throughout the company,” Crowley said.